Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air® App

BACKGROUND

In allergic rhinitis, a relevant outcome providing information on the effectiveness of interventions is needed. In MASK-air (Mobile Airways Sentinel Network), a visual analogue scale (VAS) for work is used as a relevant outcome. This study aimed to assess the performance of the work VAS work by comparing VAS work with other VAS measurements and symptom-medication scores obtained concurrently.

METHODS

All consecutive MASK-air users in 23 countries from 1 June 2016 to 31 October 2018 were included (14 189 users; 205 904 days). Geolocalized users self-assessed daily symptom control using the touchscreen functionality on their smart phone to click on VAS scores (ranging from 0 to 100) for overall symptoms (global), nose, eyes, asthma and work. Two symptom-medication scores were used: the modified EAACI CSMS score and the MASK control score for rhinitis. To assess data quality, the intra-individual response variability (IRV) index was calculated.

RESULTS

A strong correlation was observed between VAS work and other VAS. The highest levels for correlation with VAS work and variance explained in VAS work were found with VAS global, followed by VAS nose, eye and asthma. In comparison with VAS global, the mCSMS and MASK control score showed a lower correlation with VAS work. Results are unlikely to be explained by a low quality of data arising from repeated VAS measures.

CONCLUSIONS

VAS work correlates with other outcomes (VAS global, nose, eye and asthma) but less well with a symptom-medication score. VAS work should be considered as a potentially useful AR outcome in intervention studies.

ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle

The Allergic Rhinitis and its Impact on Asthma (ARIA) initiative commenced during a World Health Organization workshop in 1999. The initial goals were (1) to propose a new allergic rhinitis classification, (2) to promote the concept of multi-morbidity in asthma and rhinitis and (3) to develop guidelines with all stakeholders that could be used globally for all countries and populations. ARIA—disseminated and implemented in over 70 countries globally—is now focusing on the implementation of emerging technologies for individualized and predictive medicine. MASK [MACVIA (Contre les Maladies Chroniques pour un Vieillissement Actif)-ARIA Sentinel NetworK] uses mobile technology to develop care pathways for the management of rhinitis and asthma by a multi-disciplinary group and by patients themselves. An app (Android and iOS) is available in 20 countries and 15 languages. It uses a visual analogue scale to assess symptom control and work productivity as well as a clinical decision support system. It is associated with an inter-operable tablet for physicians and other health care professionals. The scaling up strategy uses the recommendations of the European Innovation Partnership on Active and Healthy Ageing. The aim of the novel ARIA approach is to provide an active and healthy life to rhinitis sufferers, whatever their age, sex or socio-economic status, in order to reduce health and social inequalities incurred by the disease.

Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5)

Action Plan B3 of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) focuses on the integrated care of chronic diseases. Area 5 (Care Pathways) was initiated using chronic respiratory diseases as a model. The chronic respiratory disease action plan includes (1) AIRWAYS integrated care pathways (ICPs), (2) the joint initiative between the Reference site MACVIA-LR (Contre les MAladies Chroniques pour un VIeillissement Actif) and ARIA (Allergic Rhinitis and its Impact on Asthma), (3) Commitments for Action to the European Innovation Partnership on Active and Healthy Ageing and the AIRWAYS ICPs network. It is deployed in collaboration with the World Health Organization Global Alliance against Chronic Respiratory Diseases (GARD). The European Innovation Partnership on Active and Healthy Ageing has proposed a 5-step framework for developing an individual scaling up strategy: (1) what to scale up: (1-a) databases of good practices, (1-b) assessment of viability of the scaling up of good practices, (1-c) classification of good practices for local replication and (2) how to scale up: (2-a) facilitating partnerships for scaling up, (2-b) implementation of key success factors and lessons learnt, including emerging technologies for individualised and predictive medicine. This strategy has already been applied to the chronic respiratory disease action plan of the European Innovation Partnership on Active and Healthy Ageing.

MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation

Several unmet needs have been identified in allergic rhinitis: identification of the time of onset of the pollen season, optimal control of rhinitis and comorbidities, patient stratification, multidisciplinary team for integrated care pathways, innovation in clinical trials and, above all, patient empowerment. MASK-rhinitis (MACVIA-ARIA Sentinel NetworK for allergic rhinitis) is a simple system centred around the patient which was devised to fill many of these gaps using Information and Communications Technology (ICT) tools and a clinical decision support system (CDSS) based on the most widely used guideline in allergic rhinitis and its asthma comorbidity (ARIA 2015 revision). It is one of the implementation systems of Action Plan B3 of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA). Three tools are used for the electronic monitoring of allergic diseases: a cell phone-based daily visual analogue scale (VAS) assessment of disease control, CARAT (Control of Allergic Rhinitis and Asthma Test) and e-Allergy screening (premedical system of early diagnosis of allergy and asthma based on online tools). These tools are combined with a clinical decision support system (CDSS) and are available in many languages. An e-CRF and an e-learning tool complete MASK. MASK is flexible and other tools can be added. It appears to be an advanced, global and integrated ICT answer for many unmet needs in allergic diseases which will improve policies and standards.

Integrated care pathways for airway diseases (AIRWAYS-ICPs)

The objective of Integrated Care Pathways for Airway Diseases (AIRWAYS-ICPs) is to launch a collaboration to develop multi-sectoral care pathways for chronic respiratory diseases in European countries and regions. AIRWAYS-ICPs has strategic relevance to the European Union Health Strategy and will add value to existing public health knowledge by: 1) proposing a common framework of care pathways for chronic respiratory diseases, which will facilitate comparability and trans-national initiatives; 2) informing cost-effective policy development, strengthening in particular those on smoking and environmental exposure; 3) aiding risk stratification in chronic disease patients, using a common strategy; 4) having a significant impact on the health of citizens in the short term (reduction of morbidity, improvement of education in children and of work in adults) and in the long-term (healthy ageing); 5) proposing a common simulation tool to assist physicians; and 6) ultimately reducing the healthcare burden (emergency visits, avoidable hospitalisations, disability and costs) while improving quality of life. In the longer term, the incidence of disease may be reduced by innovative prevention strategies. AIRWAYSICPs was initiated by Area 5 of the Action Plan B3 of the European Innovation Partnership on Active and Healthy Ageing. All stakeholders are involved (health and social care, patients, and policy makers).

Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs

Allergic rhinitis (AR) and asthma represent global health problems for all age groups. Asthma and rhinitis frequently coexist in the same subjects. Allergic Rhinitis and its Impact on Asthma (ARIA) was initiated during a World Health Organization workshop in 1999 (published in 2001). ARIA has reclassified AR as mild/moderate-severe and intermittent/persistent. This classification closely reflects patients' needs and underlines the close relationship between rhinitis and asthma. Patients, clinicians, and other health care professionals are confronted with various treatment choices for the management of AR. This contributes to considerable variation in clinical practice, and worldwide, patients, clinicians, and other health care professionals are faced with uncertainty about the relative merits and downsides of the various treatment options. In its 2010 Revision, ARIA developed clinical practice guidelines for the management of AR and asthma comorbidities based on the Grading of Recommendation, Assessment, Development and Evaluation (GRADE) system. ARIA is disseminated and implemented in more than 50 countries of the world. Ten years after the publication of the ARIA World Health Organization workshop report, it is important to make a summary of its achievements and identify the still unmet clinical, research, and implementation needs to strengthen the 2011 European Union Priority on allergy and asthma in children.

Severe chronic allergic (and related) diseases: a uniform approach--a MeDALL--GA2LEN--ARIA position paper

Concepts of disease severity, activity, control and responsiveness to treatment are linked but different. Severity refers to the loss of function of the organs induced by the disease process or to the occurrence of severe acute exacerbations. Severity may vary over time and needs regular follow-up. Control is the degree to which therapy goals are currently met. These concepts have evolved over time for asthma in guidelines, task forces or consensus meetings. The aim of this paper is to generalize the approach of the uniform definition of severe asthma presented to WHO for chronic allergic and associated diseases (rhinitis, chronic rhinosinusitis, chronic urticaria and atopic dermatitis) in order to have a uniform definition of severity, control and risk, usable in most situations. It is based on the appropriate diagnosis, availability and accessibility of treatments, treatment responsiveness and associated factors such as comorbidities and risk factors. This uniform definition will allow a better definition of the phenotypes of severe allergic (and related) diseases for clinical practice, research (including epidemiology), public health purposes, education and the discovery of novel therapies.

[Domestic and occupational pneumo-allergens among workers with tropical wood in Abidjan (Ivory Coast)]

The authors realized an epidemiologic research by skin test method in a furniture factory in Abidjan (Ivory Coast). 19 wood workers underwent these tests: their professional risk to wood dust exposure was over 13 years. The results show the importance of allergenic work atmosphere and mainly the high allergic potential of five exotic woods currently used. This article proposes an approach of the specific immunological pathways through a prospective allergological enquiry conducted at furniture factory in Abidjan (Ivory Coast).

Spirometric reference values in Senegalese black adults

Spirometric volumes and expiratory flows were measured among 448 Senegalese males and females of 25-80 yrs of age. The values obtained are similar to those reported for black Africans and black Americans in the literature. Volumes are 15-25% lower in males and 23% lower in females than in Caucasians. Forced expiratory flow between 25-75% of vital capacity (VC), (FEF25-75) is 5-18% lower in males and 19% lower in females. FEF25-75/VC ratio is higher in blacks than in Whites, but the forced expiratory volume in one second FEV1/VC ratio is similar in black and white subjects. However, we cannot use proportional factors to determine spirometric black standards from white reference values, so, equations of regression and nomograms with age and height are proposed for black Africans.

Spirometric reference values in Senegalese black adults

Spirometric volumes and expiratory flows were measured among 448 Senegalese males and females of 25-80 yrs of age. The values obtained are similar to those reported for black Africans and black Americans in the literature. Volumes are 15-25% lower in males and 23% lower in females than in Caucasians. Forced expiratory flow between 25-75% of vital capacity (VC), (FEF25-75) is 5-18% lower in males and 19% lower in females. FEF25-75/VC ratio is higher in blacks than in Whites, but the forced expiratory volume in one second FEV1/VC ratio is similar in black and white subjects. However, we cannot use proportional factors to determine spirometric black standards from white reference values, so, equations of regression and nomograms with age and height are proposed for black Africans.

[Reference values for maximal midexpiratory flow in black females]

The aim of this publication is to contribute to the establishment of reference values for the forced expiratory flow between 25 and 75% of the vital capacity (FEF25-75) among black females in West Africa. 316 of them, aged between 10 and 70 years, were submitted to this test. They were considered free from cardiopulmonary disease after a questionnaire and clinical examination. FEF25-75 in absolute value was lower than in the white Euro-americans. It increased up to 18-19 years of age, then decreased steadily thereafter. The main equations of regression for the FEF25-75 (l X s-1) were: 10-18 years, 0.177A + 1.058 and 0.157A + 0.826H + 0.005; 19-70 years, -0.028A + 4.211 and -0.025A + 2.206H + 0.512, (where A is the age in years and H the height in metres). The results are compared with the reference values published in Black Africa, Europe and the United States.

[Spirometric reference values in black females]

The aim of this paper is to give spirometric reference values for black females. Having eliminated those with abnormal hemoglobin, we studied 298 females aged between 10 to 70 years: 15 from bordering countries of the Ivory Coast and the others being Ivorian. That is, they are all from West Africa. It is shown that FVC and FEV1 are reduced in the black population when compared with European whites. Volume and flow values are also lower than those in Ivorian men. Correlations and linear regression equations were calculated between FVC, FEV1 and age, height, and weight. FVC and FEV1 (l BTPS) were found as a function of height H (m) and age A (years) as follows: from 10 to 25 years, FVC = 0.465 H3 + 0.01735 A + 0.58; FEV1 = 0.451 H3 + 0.0035 A + 0.61; from 25 to 70 years, FVC = 0.450 H3 - 0.02002 A + 1.54; FEV1 = 0.309 H3 - 0.02050 A + 1.44.

[Mediastino-pulmonary sarcoidosis in Ivory Coast. Epidemiological and clinical significance of sixteen new cases observed in Abidjan (author's transl)]

Sixteen cases of mediastion-pulmonary sarcoïdosis are reported, half of them presenting extra-thoracic associated lesions. The clinical and epidemiological study of these cases, compared to the previously published ones, demonstrates that the clinical features are similar in Africans and Black Americans and that the disease in coming out in Africa South of the Sahara.